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Finally, in our study, all patients were able to activate easily the
Algomed system at the time of prodromal symptoms, and injection
of phenylephrine was effective in every patient. These results
indicate that the modified Algomed pump is an efficient prototype
of a patient-activated DDS for the treatment of VVS during
HUTT. Obviously, our data are experimental, and further studies
are needed to confirm these laboratory results in clinical practice.
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Association of Smoking With Improved Myocardial Perfusion and the Angiographic
Characterization of Myocardial Tissue Perfusion After Fibrinolytic Therapy for
ST-Segment Elevation Myocardial Infarction
To the Editor: ST-segment elevation myocardial infarction
(STEMI) may arise from different pathophysiologic processes
ranging from plaque rupture to endothelial surface erosion. In the
latter case, exposure of a denuded endothelium to a “high-risk
blood phenotype” of elevated procoagulant factors and activated
inflammatory cells may be the major trigger for thrombus forma-
tion. In particular, cigarette smoking is associated with increases in
circulating fibrinogen and tissue factor (1), suggesting that throm-
bus in smokers with STEMI may be more fibrin-rich and,
therefore, more amenable to fibrinolytic therapy.
Despite an increased risk of developing myocardial infarction,
smokers with STEMI have a lower mortality compared with
nonsmokers. This was first noted in the Thrombolysis In Myo-
cardial Infarction (TIMI)-2 trial and has been largely attributed to
fewer comorbidities and younger age among smokers. However,
smoking has also been independently associated with lower mor-
tality (2) and with better epicardial flow after fibrinolytic therapy
(3). Although we were unable to detect differences in myocardial
perfusion among a limited number of patients from older fibrino-
lytic trials (4), we hypothesized that in a larger population treated
with current fibrinolytic therapy, smoking might be associated
with improved myocardial perfusion as a potential unidentified
explanation of the “smokers’ paradox.”
Data were drawn from patients in the Integrilin and Tenecteplase
in Acute Myocardial Infarction (INTEGRITI), Enoxaparin and
Thrombolysis Reperfusion for Acute Myocardial Infarction
Table 1. Blood Pressure and Heart Rate During HUTT With Placebo and Phenyilephrine
Injection
Physician Test (n  15) Patient Test (n  10)
Phenylephrine Placebo Phenylephrine Placebo
Systolic blood pressure (mm Hg)
Supine 141 20 129  23 140 16 142  16
Tilting start 144 23 128  24 149 18 144  10
Symptoms onset 105 19 96  21 122 23 106  20
Injection 62  13 61  14 76 16 74  10
End point 121 19* 50  13 116 32* 59  9
Maximum effect 175 35 177  19
Diastolic blood pressure (mm Hg)
Supine 73  12 68  14 74 14 73  11
Tilting start 82  14 76  16 87 3 85  6
Symptoms onset 65  12 62  19 78 15 72  11
Injection 44  11 45  14 55 13 51  10
End point 73  10* 37  12 79 20* 39  8
Maximum effect 100 16 102  10
Heart rate (beats/min)
Supine 77  16 75  12 72 10 74  13
Tilting start 85  19 93  15 87 11 88  12
Symptoms onset 97  26 97  24 99 21 105  15
Injection 81  30 88  27 96 26 98  22
End point 68  25 75  21 70 21 75  26
Maximum effect 59 21 55  13
*Phenylephrine vs. placebo: p  0.01 (two-tailed paired Student t test).
End point  syncope or normal state of consciousness; HUTT  head-up tilt test.
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(ENTIRE-TIMI 23), and Fibrinolytics and Aggrastat with ST
segment Resolution (FASTER) trials of reduced-dose fibrinolytic
therapy with glycoprotein IIb/IIIa inhibitors for STEMI. Patients
reporting active cigarette use were classified as smokers.
Angiographic analyses were performed by a core laboratory.
Sixty-minute TIMI flow grade (TFG), corrected TIMI frame
count (CTFC), and TIMI myocardial perfusion grade (TMPG)
were assessed as previously described. Offline digital subtraction
angiography (DSA) was performed, and blush intensity and rate of
increase in blush intensity were quantified using a gray scale
standard. The percentage of ST-segment resolution at 60 min was
also assessed as a measure of myocardial perfusion.
All analyses were performed using Stata version 7.0 (Stata
Corp., College Station, Texas). Continuous variables are reported
as median values with 25% to 75% interquartile values, unless
otherwise specified. Chi-square, Wilcoxon rank-sum, and Student
t tests were used as appropriate. Backward stepwise logistic
regression (p  0.05 for entry, p  0.10 for retention) was
performed with TMPG as the outcome, incorporating smoking
status, baseline characteristics, and known covariates of TMPG. A
propensity score for smoking was used as a further adjustment in
the model and in matching two cohorts of smokers and nonsmok-
ers derived from the overall sample (5).
Of the 1,313 patients, smokers were younger, with a lower
proportion of previous diabetes, hypertension, and hyperlipidemia,
reduced number of medications, shorter time from symptom onset
to treatment, and slightly lower blood pressure (Table 1). How-
ever, smokers had higher a white blood cell count (WBCC),
hemoglobin, platelet counts, and C-reactive protein (CRP). There
was no difference in the use of glycoprotein IIb/IIIa inhibitors
between smokers and nonsmokers.
The incidence of multivessel disease was lower in smokers (p 
0.02). There were no significant differences in infarct artery
location, lesion complexity, presence of residual thrombus, mini-
mum lumen diameter, or percent stenosis among smokers com-
pared with nonsmokers. Although the rate of 60-min TFG 3 was
slightly higher and the CTFC was slightly faster among smokers,
these differences were not statistically significant.
Smokers had improved myocardial perfusion by TMPG com-
pared with nonsmokers (for TMPG 2/3: 59.2% vs. 47.9%, p 
0.001; for TMPG 3: 56.1% vs. 46.1%, p 0.001). The association
between smoking and improved TMPG was most pronounced
among patients with patent epicardial arteries (Fig. 1) and among
low- to moderate-risk patients in analyses stratified by TIMI risk
score (TRS). Even among patients with TFG 3, smoking was
associated with improved myocardial perfusion (76.8% TMPG 2/3
vs. 66.9%, p 0.006). Smokers also had brighter blush intensity (p
 0.02) and a faster rate of increase in blush intensity (p  0.01)
quantified using DSA. The median ST-segment resolution was
greater in smokers compared with nonsmokers (p  0.026).
Smoking was associated with better myocardial perfusion after
adjusting for differences in baseline characteristics, angiographic
Table 1. Baseline Characteristics
Nonsmokers (n  644) Smokers (n  669) p Value
Male gender (%) 79.5 (512/1,045) 79.7 (533/1,045) 0.94
Previous diabetes (%) 19.3 (124/186) 9.3 (62/186) 0.001
Previous hypertension (%) 36.2 (233/394) 24.1 (161/394) 0.001
Previous hyperlipidemia (%) 28.1 (181/328) 22.0 (147/328) 0.010
Previous coronary artery disease (angina or
revascularization) (%)
39.1 (252/493) 36.0 (241/493) 0.245
Previous aspirin (%) 37.1 (239/446) 31.0 (207/446) 0.019
Previous beta-blocker (%) 21.3 (137/252) 17.2 (115/252) 0.060
Previous ACE inhibitor (%) 13.5 (87/137) 7.5 (50/137) 0.001
Previous antihyperlipidemic (%) 16.6 (107/179) 10.8 (72/179) 0.002
Killip class 2–4 (%) 8.3 (53/108) 8.4 (55/108) 0.98
Combination therapy with glycoprotein IIb/IIIa
inhibitor (%)
65.1 (418/841) 63.6 (423/841) 0.57
Age (yrs) 62 (54, 70) (n 644) 53 (47, 61) (n 669) 0.001
Heart rate on admission (beats/min) 72 (62, 85) (n 642) 72 (61, 86) (n 669) 0.70
Systolic blood pressure (mm Hg) on admission 140 (129, 160) (n 643) 137 (121, 150) (n 669) 0.001
Baseline white blood cell count (106/ml) 9.6 (7.6, 11.8) (n 419) 11.2 (9.1, 13.8) (n 430) 0.001
Baseline C-reactive protein (mg/l) 2.5 (1.0, 5.2) (n 286) 3.2 (1.5, 7.2) (n 318) 0.002
Baseline hemoglobin (g/dl) 14.6 (13.8, 15.4) (n 634) 15.0 (14.1, 15.9) (n 657) 0.001
Baseline platelet count (103/ml) 237 (201, 275) (n 626) 250 (214, 294) (n 652) 0.001
Time to treatment (h) 3.0 (2.2, 4.0) (n 636) 2.8 (2.0, 3.8) (n 659) 0.004
Data are presented as the percentage (%) or median value (25th, 75th percentiles).
ACE  angiotensin-converting enzyme.
Figure 1. Smoking status and 60-min TIMI myocardial perfusion grade
(TMPG) 2/3 stratified by TIMI flow grade (TFG). Solid bars smokers;
open bars  nonsmokers.
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lesion characteristics, glycoprotein IIb/IIIa inhibitor use, and TFG
3 (odds ratio [OR] for TMPG 2/3 of 1.7, 95% confidence interval
[CI] 1.3 to 2.3, n  1,068, p  0.001). This association persisted
despite the inclusion of the propensity score for smoking, as well as
in a model incorporating WBCC, hemoglobin, platelet count, and
CRP (OR 2.0, CI 1.3 to 3.1, n  461, p  0.001). Finally, when
the propensity score was used to generate matched cohorts of
smokers and nonsmokers, the magnitude of the association be-
tween smoking and higher TMPG was similar to that in the
overall unmatched population.
This analysis demonstrates that smokers with STEMI have im-
proved myocardial perfusion after fibrinolytic therapy, as compared
with nonsmokers, despite adjustment for differences in age, comor-
bidities, previous medications, and other potential confounders, and
additionally in analyses stratified by TFG and TRS. This finding
lends support to the hypothesis that smokers have more complete clot
lysis after fibrinolytic administration, which results in improved
myocardial perfusion independent of epicardial artery flow. Smoking
has been associated with better clinical outcomes after fibrinolytic
administration in STEMI patients, but the underlying mechanism
responsible for the so-called “smoker’s paradox” remains unclear.
Several angiographic analyses have demonstrated faster epicardial flow
among smokers, independent of baseline covariates (3). Although we
observed no significant differences in 60-min epicardial flow, this may
be due to the angiographic time point used, because among patients
who had available 90-min data, the incidence of TFG 3 was
significantly higher among smokers at 90 min (data not shown).
Smoking may not increase plaque vulnerability as much as it
intensifies hypercoagulability. It is notable that the association
between smoking and improved myocardial perfusion was inde-
pendent of the higher WBCC and CRP levels in smokers. As
elevated inflammatory markers are associated with impaired myo-
cardial perfusion, this may reflect differing roles of inflammatory
markers between smokers and nonsmokers. Smoking has been
associated with higher levels of procoagulant factors (1), and
soluble components of cigarette smoke have also been shown to
impair fibrin cross-linking (6). These findings support the hypoth-
esis that the pathogenesis of STEMI in smokers may be less
atherogenic but more thrombogenic and therefore more responsive
to fibrinolytic therapy.
It could be speculated that our findings may reflect more
complete fibrinolysis with reduced distal embolization and micro-
vascular dysfunction among smokers. Although our study was not
powered to detect differences in clinical outcomes, insofar as
improvements in myocardial perfusion have been associated with
better outcomes in STEMI, the association between smoking and
better myocardial perfusion may explain, at least in part, the
improved prognosis of smokers in this clinical setting.
Spontaneous fibrinolysis and/or epicardial coronary vasospasm
may have occurred more frequently among smokers, which may be
a mechanism of a seemingly superior response to fibrinolytic
therapy. Despite efforts to adjust for baseline characteristics and
covariates, including the reperfusion regimen, this analysis is a
nonrandomized, retrospective analysis of pooled clinical trials, and
as such, it is possible that both identified and unidentified residual
confounders may have influenced the outcomes.
Smoking is independently associated with improved myocardial
perfusion after fibrinolytic therapy, despite adjustment for multiple
baseline clinical characteristics. This finding may partly explain the
improved outcomes of smokers with STEMI treated with fibrino-
lytic therapy.
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Letters to the Editor
Coronary Stenting Versus
Balloon Angioplasty in Small Vessels
We read with interest the study by Moreno et al. (1), which
demonstrated, through a meta-analytic technique, the significant
reduction of restenosis due to stent in comparison to percutaneous
transluminal coronary angioplasty in small-vessel coronary artery
disease. However, the investigators failed to emphasize that
substantial statistical heterogeneity was present, as shown in their
overall analysis in Figure 1 (p for heterogeneity  0.019).
We believe that this constitutes a methodological flaw in the
study. Indeed, substantial heterogeneity is considered by several
investigators to be a contraindication to quantitative pooling
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